Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Influence of the area of the aqueduct and region of interest on quantification of stroke volume in healthy volunteers using phase-contrast cine magnetic resonance imaging
Zhang, Hongri , Yang, Haixin, Duan, Weike , Elder, Benjamin D. , Duan, Weike, Li, Xiaopan , Wang, Yixin, Cogswell, Petrice M.

Mayo Clinic

Acta Radiologica | September 15, 2022 | Volume: 64 | Issue: 4 | Pages: 1615-1622

10.1177/02841851221125916 | PMID 37023028 Get It

Background Phase-contrast cine magnetic resonance imaging (PC-MRI) has been used to measure cerebrospinal fluid (CSF) flow dynamics, but the influence of the area of the aqueduct and region of interest (ROI) on quantification of stroke volume (SV) has not been assessed. Purpose To assess the influence of the area of the ROI in quantifying the aqueductal SV measured with PC-MRI within the cerebral aqueduct. Material and Methods Nine healthy volunteers (mean age = 29.6 years) were enrolled in the study, and brain MRI examinations were performed on a 3.0-T system. Quantitative analysis of the aqueductal CSF flow was performed using manual ROI placement. ROIs were separately drawn for each of the 12 phases of the cardiac cycle, and changes in aqueduct size during the cardiac cycle were determined. The SV was calculated using 12 different aqueductal ROIs and compared with the SV calculated using a fixed ROI size. Results There was variation in the size of the aqueduct during the cardiac cycle. In addition, the measured SV increased with a greater area of the ROI. A significant difference in the calculated SVs with the 12 variable ROIs was observed compared with that using a fixed ROI throughout the cardiac cycle. Conclusion To establish reliable reference values for the SV in future studies, a variable ROI should be considered.
Histological assessment of new cholangioscopy-guided forceps in ERCP biliary stricture sampling: a blinded comparative study
Chen, Zongming Eric, Abusaleh, Rami R., Martin, John A. , Law, Ryan , Levy, Michael J. , Petersen, Bret T. , Law, Ryan J, Petersen, Bret, Vargas, Eric J. , Wang, Yaohong , Abusaleh, Rami , Storm, Andrew C. , Dayyeh, Barham K. Abu , Levy, Michael J. , Petersen, Bret T. , Chandrasekhara, Vinay

Mayo Clinic

Endoscopy International Open | September 14, 2022 | Volume: 10 | Issue: 09 | Pages: E1233-E1237

10.1055/a-1897-4686 | PMID 36118635 Get It

Abstract Background and study aims Obtaining quality tissue during ERCP biliary stricture sampling is of paramount importance for a timely diagnosis. While single-operator cholangioscopy (SOC)-guided biopsies have been suggested to be the superior biliary tissue acquisition modality given direct tissue visualization, less is known about the specimen histological quality. We aimed to analyze the specimen quality of SOC biopsies and compare the new generation forceps with prior “legacy” forceps. Patients and methods Patients who underwent SOC from January 2017-August 2021 for biliary sampling were reviewed. In February 2020, the SOC-guided biopsy forceps were changed from legacy SpyBite to the SpyBite Max forceps (max). Specimens were assessed by blinded pathologists for crush artifact (none, mild, or severe) and gross size (greatest dimension in mm). Crush artifact and gross size were compared between the two groups. The diagnostic performance characteristics for cholangiocarcinoma (CCA), were assessed in an exploratory fashion. Results Eighty-one patients (max = 27, legacy = 54) with similar baseline characteristics were included in this study. On blinded pathological assessment, 58 % had crush artifact, without significant differences between the two groups (Max 63 % vs. Legacy 56 %; P = 0.64). A similar mean specimen size was found (max 3 mm vs. legacy 3.2 mm; P = 0.24). The overall prevalence of CCA was 40 %. The sensitivity, specificity, positive predictive value, and negative predictive value of the entire cohort using a combination of cytology, fluorescence in situ hybridization, and SOC-guided biopsies were 78.1 %, 91.8 %, 86.2 %, and 86.5 %, respectively. No difference between legacy or max groups was found. Conclusions A high rate of crush artifact was found in SOC-guided biopsy specimens. Further investigation regarding proper biopsy technique and handling is necessary to increase the diagnostic yield with SOC-guided biopsies.
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Hajnik, Renee L. , Plante, Jessica A. , Liang, Yuejin , Alameh, Mohamad‐Gabriel , Tang, Jinyi , Bonam, Srinivasa Reddy , Zhong, Chaojie, Adam, Awadalkareem, Scharton, Dionna , Rafael, Grace, Liu, Yang , Hazell, Nicholas C., Sun, Jiaren , Shi, Pei‐Yong , Wang, Tian , Walker, David H. , Plante, Kenneth S. , Soong, Lynn , Shi, Pei-Yong , Wang, Tian , Sun, Jie , Weissman, Drew , Weaver, Scott C , Plante, Kenneth S , Hu, Haitao , Tang, J , Liu, Yang , Sun, Jie

Mayo Clinic

Science Translational Medicine | September 14, 2022 | Volume: 14 | Issue: 662 | Pages: No page available

10.1126/scitranslmed.abq1945 | PMID 36103514 Get It

Emergence of SARS-CoV-2 variants of concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines that principally target the viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine that expresses the more conserved viral nucleoprotein (mRNA-N) and show that mRNA-N vaccination alone can induce modest control of SARS-CoV-2. Critically, combining mRNA-N with the clinically proven S-expressing mRNA vaccine (mRNA-S+N) induced robust protection against both Delta and Omicron variants. In the hamster models of SARS-CoV-2 VOC challenge, we demonstrated that, compared to mRNA-S alone, combination mRNA-S+N vaccination not only induced more robust control of the Delta and Omicron variants in the lungs but also provided enhanced protection in the upper respiratory tract. In vivo CD8 + T cell depletion suggested a potential role for CD8 + T cells in protection conferred by mRNA-S+N vaccination. Antigen-specific immune analyses indicated that N-specific immunity, as well as augmented S-specific immunity, was associated with enhanced protection elicited by the combination mRNA vaccination. Our findings suggest that combined mRNA-S+N vaccination is an effective approach for promoting broad protection against SARS-CoV-2 variants.
Homologous recombination–deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants
Prakash, Rohit , Rawal, Yashpal , Sullivan, Meghan R. , Grundy, McKenzie K. , Bret, Hélène , Mihalevic, Michael J., Rein, Hayley L. , Baird, Jared M. , Darrah, Kristie, Zhang, Fang , Modesti, Mauro , Jasin, Maria , Bernstein, Kara A. , Traina, Tiffany A , Kaufmann, Scott H , Swisher, Elizabeth M , Guérois, Raphaël , Modesti, Mauro , Jasin, Maria , Bernstein, Kara A , Sullivan, Meghan R. , Wang, Raymond , Radke, Marc R. , Kaufmann, Scott H. , Swisher, Elizabeth M. , Sung, Patrick

Mayo Clinic

Proceedings of the National Academy of Sciences | September 13, 2022 | Volume: 119 | Issue: 38 | Pages: No page available

10.1073/pnas.2202727119 | PMID 36099300 Get It

Mutations in homologous recombination (HR) genes, including BRCA1 , BRCA2 , and the RAD51 paralog RAD51C , predispose to tumorigenesis and sensitize cancers to DNA-damaging agents and poly(ADP ribose) polymerase inhibitors. However, ∼800 missense variants of unknown significance have been identified for RAD51C alone, impairing cancer risk assessment and therapeutic strategies. Here, we interrogated >50 RAD51C missense variants, finding that mutations in residues conserved with RAD51 strongly predicted HR deficiency and disrupted interactions with other RAD51 paralogs. A cluster of mutations was identified in and around the Walker A box that led to impairments in HR, interactions with three other RAD51 paralogs, binding to single-stranded DNA, and ATP hydrolysis. We generated structural models of the two RAD51 paralog complexes containing RAD51C, RAD51B-RAD51C-RAD51D-XRCC2 and RAD51C-XRCC3. Together with our functional and biochemical analyses, the structural models predict ATP binding at the interface of RAD51C interactions with other RAD51 paralogs, similar to interactions between monomers in RAD51 filaments, and explain the failure of RAD51C variants in binding multiple paralogs. Ovarian cancer patients with variants in this cluster showed exceptionally long survival, which may be relevant to the reversion potential of the variants. This comprehensive analysis provides a framework for RAD51C variant classification. Importantly, it also provides insight into the functioning of the RAD51 paralog complexes.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
Khanna, Sahil , Sims, Matthew , Louie, Thomas , Fischer, Monika , LaPlante, Kerry L. , Allegretti, Jessica R. , Hasson, Brooke , Fonte, Allyson T., McChalicher, Christopher , Ege, David S., Bryant, Jessica A. , Straub, Timothy J. , Ford, Christopher B. , Henn, Matthew R. , Wang, Elaine E. L., Moltke, Lisa Von, Wilcox, Mark H.

Mayo Clinic

Antibiotics | September 12, 2022 | Volume: 11 | Issue: 9 | Pages: 1234

10.3390/antibiotics11091234 | PMID 36140013 Get It

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of recurrence increases with subsequent episodes to greater than 40%. The leading risk factor for CDI is broad-spectrum antibiotics, which leads to a loss of microbial diversity and impaired colonization resistance. Current FDA-approved CDI treatment strategies target toxin or toxin-producing bacteria, but do not address microbiome disruption, which is key to the pathogenesis of recurrent CDI. Fecal microbiota transplantation (FMT) reduces the risk of recurrent CDI through the restoration of microbial diversity. However, FDA safety alerts describing hospitalizations and deaths related to pathogen transmission have raised safety concerns with the use of unregulated and unstandardized donor-derived products. SER-109 is an investigational oral microbiome therapeutic composed of purified spore-forming Firmicutes. SER-109 was superior to a placebo in reducing CDI recurrence at Week 8 (12% vs. 40%, respectively; p < 0.001) in adults with a history of recurrent CDI with a favorable observed safety profile. Here, we discuss the role of the microbiome in CDI pathogenesis and the clinical development of SER-109, including its rigorous manufacturing process, which mitigates the risk of pathogen transmission. Additionally, we discuss compositional and functional changes in the gastrointestinal microbiome in patients with recurrent CDI following treatment with SER-109 that are critical to a sustained clinical response.
Mining Transportation Issues from Patient Portal Messages
Wang, Nan , Huang, Ming , Fan, Jungwei

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 532-533

10.1109/ichi54592.2022.00100 Get It

MedTator: A Serverless Web-based Tool for Corpus Annotation
Wang, Liwei , He, Huan , Fu, Sunyang , Wen, Andrew , Liu, Sijia , Liu, Hongfang

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 530-531

10.1109/ichi54592.2022.00099 Get It

Evaluation of mCODE Coverage in EHR: a Scoping Review of Cancer Natural Language Processing
Wang, Liwei , Ruan, Xiaoyang , Mai, Michelle , Wang, Nan , Xu, Hua , Fu, Sunyang , Wen, Andrew , He, Huan , Liu, Sijia , Moon, Sungrim , Riaz, Irbaz Bin , Yang, Ping , Warner, Jeremy L. , Liu, Hongfang

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 517-518

10.1109/ichi54592.2022.00094 Get It

Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Banerjee, Imon , Jeong, Jiwoong , R, Amith Seri, Barry, Timothy , Neuman, Hana, Campany, Megan , Abdou, Merna , O'Shea, Michael P., Smith, Sean B. , Abraham, Bishoy , Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher, Shen, Win‐Kuang , Grogan, Martha , Kane, G C, Oh, Jae K. , Patel, Bhavik N. , Banerjee, Imon , Li, James , Chao, Chieh‐Ju , O’Shea, Michael, Alsidawi, Said , Oh, Jae K. , Arsanjani, Reza

Mayo Clinic

No container title available | September 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166257188.84471102/v1 Get It

Aims Increased LV wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 to 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4 chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: CA: 0.90, HCM: 0.93, and HTN/other: 0.92). Conclusion The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Safety of Scrambler Therapy: A Systematic Review of Complications and Adverse Effects
Wang, Eric J. , Limerick, Gerard, D’Souza, Ryan S. , Lobner, Katie , Williams, Kayode , Cohen, Steven P. , Smith, Thomas J. , Smith, Thomas J , Cohen, Steven P , D'Souza, Ryan S , Wang, Eric

Mayo Clinic

Pain Medicine | September 6, 2022 | Volume: 24 | Issue: 3 | Pages: 325-340

10.1093/pm/pnac137 | PMID 36069623 Get It

AbstractObjectiveThe objective was to qualitatively synthesize all reported cases of complications, adverse effects, side effects, or harms arising from the use of scrambler therapy (ST).Methods and DesignA systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The PubMed, Embase, Scopus, Web of Science, United States National Library of Medicine clinical trials registry, and Cochrane Central Register of Controlled Trials databases were searched from database inception to December 10, 2021. Case reports/series, abstracts, retrospective studies, and prospective studies (e.g., open-label trials, randomized controlled trials) pertaining to ST and any description of a complication, adverse effect, side effect, or harm were screened. The search protocol was developed a priori and registered via the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42021291838).ResultsA total of six RCTs, 19 prospective open-label trials, and 11 case series / case reports met the inclusion criteria, comprising 1,152 total patients. Two patients experienced contact dermatitis, and one patient reported minor ecchymosis that resolved without intervention. This yielded a composite complication rate of 0.26% (3/1,152). There were zero reported serious adverse events.ConclusionsWhen used in accordance with the treatment protocols described by the United States Food and Drug Administration and device manual, ST is associated with a reported composite complication rate that is orders of magnitude lower than those of invasive neuromodulation devices. ST neuromodulation is a safe alternative for patients who cannot undergo invasive neuromodulation device implantation because of either risk or preference.